Keyphrases
Ovarian Cancer
100%
Monotherapy
100%
Meta-analysis
100%
Mammalian Target of Rapamycin (mTOR)
100%
PI3K-AKT-mTOR Pathway
100%
Pathway Inhibitors
100%
Clinical Benefit Rate
85%
MTOR Inhibitor
71%
Recurrent Ovarian Cancer
42%
Patient Selection
42%
Adverse Events
28%
Drug Dependence
28%
Ovarian Cancer Patients
28%
Advanced Ovarian Cancer
28%
Overall Response Rate
28%
Partial Response
28%
Stable Disease
28%
Subgroup Analysis
14%
Clinical Trials
14%
Toxicity Profile
14%
Clinical Benefit
14%
Patient Benefit
14%
Beneficial Outcomes
14%
Predictive Value
14%
PubMed
14%
Embase
14%
Current Treatment
14%
Patient-centered
14%
Therapy Response
14%
Cochrane Library
14%
Protein Expression
14%
Pathway Activity
14%
Genetic Modification
14%
PTEN Protein
14%
On-state Current
14%
Medicine and Dentistry
Meta-Analysis
100%
Monotherapy
100%
Ovarian Cancer
100%
Protein Kinase B
100%
PI3K/AKT/mTOR Pathway
100%
Mammalian Target of Rapamycin Inhibitor
71%
Biological Marker
57%
Recurrent Ovarian Cancer
42%
Adverse Event
28%
Mammalian Target of Rapamycin
28%
Diseases
28%
Treatment Response
14%
Clinical Trial
14%
Patient Selection
14%
Protein Expression
14%
Subgroup Analysis
14%
Phosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase
14%
INIS
patients
100%
cancer
100%
ovaries
100%
biological markers
40%
diseases
20%
drugs
20%
values
10%
therapy
10%
clinical trials
10%
toxicity
10%
losses
10%
populations
10%
libraries
10%
proteins
10%
licenses
10%
Pharmacology, Toxicology and Pharmaceutical Science
Monotherapy
100%
Ovary Cancer
100%
Protein Kinase B
100%
Mammalian Target of Rapamycin Inhibitor
55%
Biological Marker
44%
Adverse Event
22%
Diseases
22%
Clinical Trial
11%
Phosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase
11%